(CGEN) Compugen Ltd. ANSOFF Analysis Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(CGEN) Compugen Ltd. Complete Analysis Pack
Dive Deeper Into the Growth Paths Behind the Analysis
This Compugen Ltd. Ansoff Matrix Analysis helps you quickly assess growth options across market penetration, market development, product development, and diversification in one clear framework; the page already includes a real preview of the analysis so you can judge style and substance before buying. Purchase the full version to access the complete ready-to-use report for strategy, investment, or planning purposes.
Market Penetration
Deepen COM701 solid-tumor Phase I execution
COM701 is already in Phase I solid-tumor studies, so Compugen Ltd.’s penetration play is to lift enrollment, site activity, and investigator pull in the same oncology field. That deepens clinical visibility for one existing asset, not the product mix. Stronger execution in the current trial footprint can help COM701 stand out versus other immune checkpoint programs.
Expand COM902 monotherapy presence in advanced malignancies
COM902 is already in Phase I as a monotherapy for advanced malignancies, so Compugen Ltd. can deepen market penetration by adding patients and trial sites in the same late-stage oncology setting. That should improve safety and efficacy readouts, build more dose and response data, and strengthen its case in checkpoint inhibition. With no new product needed, the main goal is to expand clinical exposure and move closer to a clearer go/no-go signal.
Advance Bapotulimab in solid-tumor development
Compugen Ltd. can use market penetration by pushing Bapotulimab, an ILDR2 antibody, deeper in the existing solid-tumor program. It is already in Phase I clinical development, so the goal is to keep momentum, broaden evidence, and strengthen confidence in the same asset. More patient data can help sharpen its immuno-oncology profile and keep attention on a differentiated mechanism already under study.
Strengthen AZD2936 NSCLC clinical footprint
AZD2936 is being developed in Phase I/II for advanced or metastatic NSCLC, the largest lung cancer subtype at about 85% of cases. That makes this a true market-penetration move: Compugen Ltd. is deepening its role in the same high-value setting rather than chasing a new indication. It also builds visibility for the TIGIT/PD-1 bispecific approach in a crowded oncology market.
- Phase I/II in advanced/metastatic NSCLC
- NSCLC is ~85% of lung cancers
- Focuses on deeper same-market uptake
- Supports TIGIT/PD-1 recognition
Leverage current collaborations for recurring program access
Compugen Ltd. can deepen market penetration by reusing its existing collaborations with Bayer, Bristol-Myers Squibb, Johns Hopkins School of Medicine, and AstraZeneca across current immuno-oncology programs. For a clinical-stage company with no marketed product, repeated partner-led validation helps keep its platform visible and credible without changing the core portfolio. This is a low-friction way to expand access and signal traction across 4 active collaboration anchors.
- Reuses 4 existing partnerships
- Supports proof through external validation
- Fits no-product, clinical-stage strategy
Compugen’s growth hinges on deeper oncology trial enrollment
Compugen Ltd.’s market penetration is about deepening use of existing oncology assets in the same trial settings, not adding new products. The clearest move is to expand patient enrollment, sites, and partner visibility in Phase I/II programs for COM701, COM902, Bapotulimab, and AZD2936, especially in advanced NSCLC, which is about 85% of lung cancers.
| Asset | Stage | Penetration angle |
|---|---|---|
| AZD2936 | Phase I/II | Deepen NSCLC uptake |
| COM701 | Phase I | Lift enrollment |
What is included in the product
Detailed Word Document
Analyzes Compugen Ltd.’s growth strategy through the four core directions of the Ansoff Matrix
Editable Excel File
Helps Compugen Ltd quickly clarify growth pain points with a simple Ansoff matrix for faster strategic decisions.
Reference Sources
Lists vetted primary and secondary sources that validate Compugen Ltd. growth-path assumptions for Ansoff Matrix decisions, speeding due diligence and traceable verification.
Market Development
Use COM701 with Opdivo in new treatment settings
Compugen and Bristol Myers Squibb are testing COM701 plus Opdivo in advanced solid tumors, pushing the anti-PVRIG antibody beyond single-agent use. The move taps a PD-1 regimen market led by Opdivo, which generated $9.2 billion in 2024 sales. If the combo works, Compugen can expand one asset into a broader partner-backed clinic.
Broaden COM902 beyond its monotherapy trial base
COM902 is already being tested as a monotherapy in advanced malignancies, so Compugen Ltd. can widen use into broader late-stage oncology patient segments without changing the antibody. As clinical readouts mature, the same asset can move into new tumor cohorts or biomarker-defined groups. That is market development: same drug class, bigger addressable use.
Position AZD2936 in a large NSCLC patient market
Compugen Ltd.'s AZD2936 is moving through Phase I/II in advanced or metastatic NSCLC, a huge target where lung cancer still drives about 2.5 million new cases a year globally, and NSCLC makes up roughly 85% of them. That gives AZD2936 a clear market-development path: use the same immuno-oncology asset in a much larger patient pool. If it works, the addressable market widens fast.
Translate myeloid checkpoint research into new clinical segments
Compugen Ltd. can move myeloid checkpoint work into new clinical segments by using the same platform in Johns Hopkins translational studies, which broadens testing beyond one tumor setting. This fits an Ansoff market development play: new patient groups, same core science. Myeloid programs stay earlier stage, so the main value is faster proof of biology and cleaner clinical selection.
- Same platform, new clinical segments
- Johns Hopkins adds translational depth
- Earlier-stage risk, broader upside
Extend alliance-led development into external oncology networks
Compugen Ltd. can extend alliance-led development into external oncology networks by using its four named links with Bayer, AstraZeneca, Bristol Myers Squibb, and Johns Hopkins. For a clinical-stage company, these channels help move existing programs into new trial ecosystems, expand data access, and lower the cost of finding the right partners and sites.
- 4 external oncology relationships
- New trial ecosystems for current assets
- Broader research and site access
- Market access without new product launches
Compugen Expands Into Large Cancer Markets Without Starting From Scratch
Compugen Ltd. is pursuing market development by moving the same immuno-oncology assets into larger late-stage cancer settings, including COM701 plus Opdivo, which sits in a PD-1 market led by Opdivo at $9.2 billion in 2024 sales. AZD2936 targets NSCLC, a disease with about 2.5 million new cases a year, and NSCLC is roughly 85% of lung cancers. That widens reach without starting from zero.
| Program | Market move | Size |
|---|---|---|
| COM701+Opdivo | New combo use | $9.2B Opdivo sales |
| AZD2936 | NSCLC expansion | 2.5M lung cases |
Preview Before You Purchase
Compugen Ltd. Reference Sources
This is the actual Ansoff Matrix analysis document you’ll receive upon purchase—no surprises, just professional quality.
Product Development
Build COM701 as an anti-PVRIG product candidate
COM701 is Compugen Ltd.’s anti-PVRIG antibody and a lead immuno-oncology asset, so it fits Ansoff product development: a new product for an existing oncology market.
The work is centered on clinical testing in solid tumors, where PVRIG biology can help lift anti-tumor immune response. Compugen reported R&D spending of $39.8 million in 2024, showing the cash load behind advancing this pipeline.
That makes COM701 a core example of internal innovation, not market expansion.
Advance COM902 as a TIGIT-targeting therapeutic antibody
Compugen Ltd. is advancing COM902 as a TIGIT-targeting therapeutic antibody already in Phase I, refining it as a distinct oncology candidate. This product development move expands the Company’s immuno-oncology pipeline with another checkpoint-directed asset, alongside its broader platform that had 2 late-stage clinical programs reported in recent disclosures. The focus is on validating safety, early activity, and differentiation before later-stage development.
Progress Bapotulimab for ILDR2-targeted therapy
Bapotulimab is Compugen Ltd.’s separate ILDR2 antibody in Phase I for solid tumors, so it fits product development by extending the same immuno-oncology area through a different checkpoint target. This gives Compugen Ltd. one more shot at pipeline depth after the early-stage readout. If it works, it can broaden its oncology mix without leaving the I-O field.
Develop AZD2936 as a TIGIT and PD-1 bispecific
AZD2936 is a Phase I/II bispecific antibody that hits 2 checkpoints, TIGIT and PD-1, so it is a clear Product Development move for Compugen Ltd. It adds a new multi-target modality versus single-antibody programs and signals a shift toward more engineered antibody formats.
2 targets: TIGIT and PD-1
Phase I/II development stage
New bispecific format vs single antibodies
Advance earlier-stage myeloid-target programs
Compugen Ltd. advancing earlier-stage myeloid-target programs fits Ansoff’s product development: it adds new pipeline assets for the same oncology market and expands beyond the current lead antibodies. These programs increase pipeline depth, improve target optionality, and can feed future candidate picks from Compugen’s discovery platform.
- Broadens the pipeline beyond lead antibodies
- Supports future candidate selection
- Targets the same oncology customer base
Compugen Deepens Oncology Pipeline With New Immuno-Oncology Assets
Compugen Ltd.’s product development is focused on adding new immuno-oncology assets to the same oncology market, led by COM701, COM902, and bapotulimab. The Company also advanced AZD2936, a TIGIT and PD-1 bispecific in Phase I/II, which deepens pipeline novelty. R&D spending was $39.8 million in 2024.
| Asset | Stage | Fit |
|---|---|---|
| COM701 | Clinical | New product |
| COM902 | Phase I | New product |
| AZD2936 | Phase I/II | Bispecific |
Diversification
Move from single-target antibodies to bispecific and multi-specific formats
Compugen Ltd. is moving from single-target antibodies into bi-specific and multi-specific formats, which adds new molecule design and development paths. The AstraZeneca license covers these immuno-oncology antibody products, so the shift is real diversification, not just a tweak to the same platform. In 2025, that matters because bi-specific programs typically need more complex CMC and clinical work than one-target antibodies.
Expand from T-cell checkpoints into myeloid science
Compugen Ltd.'s move from T-cell checkpoints into myeloid science is a clear diversification step: it adds a new oncology biology lane, not just a new asset. Its Johns Hopkins University collaboration strengthens that shift by deepening work on myeloid targets, expanding beyond its core checkpoint focus. This is a new product and new research-area play inside cancer immunology.
Use partner licensing as a different development model
Compugen Ltd. uses partner licensing to diversify how it develops and sells assets. The Bayer collaboration and AstraZeneca license show a model built on 2 external partners, not just internal R&D, so programs can move through discovery, development, and commercialization with shared risk and cost. That gives Compugen more ways to reach market than a standalone biotech path.
Combine checkpoint targets into next-generation regimens
Compugen Ltd. is diversifying beyond single-target cancer drugs by building next-generation checkpoint combinations. AZD2936 fuses TIGIT and PD-1 into one molecule, while COM701 is also being tested with Opdivo, so both programs shift from monotherapy to combination-first designs.
- AZD2936: dual-target TIGIT and PD-1
- COM701: tested with Opdivo
- Moves into novel combo regimens
- Diversifies therapeutic development paths
Broaden pipeline economics through multiple immuno-oncology programs
Compugen’s immuno-oncology portfolio spans at least 4 distinct programs: COM701, COM902, bapotulimab, and AZD2936. That spreads target and stage risk across a broader pipeline, so one setback does not define the whole story. This is classic diversification at the portfolio level inside one therapeutic area.
- 4 parallel programs reduce single-asset risk
- Separate targets and stages improve balance
- Pipeline breadth supports optionality
Compugen Broadens Immuno-Oncology Reach with New Partners and Bispecifics
Compugen Ltd.’s diversification is clear: it now spans 4 immuno-oncology programs, 2 external partners, and new biology areas beyond single-target antibodies. AZD2936 and COM701 show a move into bi-specific and combo-first design, while Johns Hopkins University expands myeloid work. That broadens target, format, and partner risk.
| Metric | Data |
|---|---|
| Programs | 4 |
| Partners | 2 |
| AZD2936 | TIGIT + PD-1 |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.